Physician profile
Charles Intenzo
NPI 1669405346
$84,644.89
in general payments reported to CMS, 2019-2025
8 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what a typical Nuclear Radiology provider received nationally (typical 2025 total: $145).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,104 · 2020: $7,560 · 2021: $48K · 2022: $5,704 · 2023: $5,670 · 2024: $7,282 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $926 · Travel and Lodging: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,600.00 |
| Food and Beverage | $925.60 |
| Travel and Lodging | $428.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 414 LLC | $82,973.76 | 2019-2024 | Kit For The Preparation of Lymphoseek (Technetium Tc 99m Tilmanocept) |
| Telix Pharmaceuticals | $1,011.52 | 2024-2025 | Illuccix |
| Hologic INC | $266.20 | 2019 | |
| Daxor Corporation | $127.64 | 2024 | Bva-100 |
| Progenics Pharmaceuticals, INC. | $124.67 | 2024 | |
| Ge Healthcare | $112.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $28.73 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Intenzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.